Actuate Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Actuate Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Actuate Therapeutics Inc.
Rating: 1.11566675
Author: Trendlyne DVM scores

about

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglu...

2.90 -0.07 (-2.36%)

75.81% Fall from 52W High

35,436

XNAS Volume

XNAS 14 May, 2026 5:30 PM (EDT)

Board Meeting

The next board meeting for Actuate Therapeutics Inc is on 22 May 2026 for the purpose of Actuate Therapeutics Inc Annual General Meeting for 2026 See details

Not Eligible

Expensive Valuation

2.7 / 100

Technically Neutral

42.0 / 100

No estimates available

Actuate Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Actuate Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglu...

75.81% Fall from 52W High

SWOT Analysis

Actuate Therapeutics Inc Live Price Chart